Home > News > pSivida Signs New Evaluation Agreement
April 5th, 2006
pSivida Signs New Evaluation Agreement
Abstract:
Global bio-nanotech company pSivida Limited (Nasdaq:PSDV)(ASX:PSD)(Xetra:PSI) today announced that it has entered into an evaluation agreement with an undisclosed large medical device company to evaluate cardiovascular delivery of drugs using pSivida's drug delivery technologies.
Source:
businesswire
Bookmark:
Nanomedicine
Single-Cell Transfection Tool Enables Added Control for Biological Studies: McCormick researchers develop method of delivering molecules into targeted cells May 22nd, 2013
How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013
MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Announcements
Single-Cell Transfection Tool Enables Added Control for Biological Studies: McCormick researchers develop method of delivering molecules into targeted cells May 22nd, 2013
Imec and GLOBALFOUNDRIES collaborate to advance high-density memory technology: STT-MRAM offers enhanced performance and scalability for embedded and standalone applications May 21st, 2013
International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013
Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013